flumbatinib   Click here for help

GtoPdb Ligand ID: 9913

Synonyms: flumatinib (pseudo INN) | Hansoh Xinfu® | HH-GV678 | HHGV-678
Approved drug
flumbatinib is an approved drug (China (2019))
Compound class: Synthetic organic
Comment: Flumatinib (HH-GV-678) is a selective, orally bioavailable inhibitor of Bcr-Abl that was developed for antineoplastic potential [1].
The INN 'flumatinib' was surfaced in WHO Proposed list 125 in July 2021.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 99.17
Molecular weight 562.24
XLogP 2.8
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1CCN(CC1)Cc1ccc(cc1C(F)(F)F)C(=O)Nc1cnc(c(c1)Nc1nccc(n1)c1cccnc1)C
Isomeric SMILES CN1CCN(CC1)Cc1ccc(cc1C(F)(F)F)C(=O)Nc1cnc(c(c1)Nc1nccc(n1)c1cccnc1)C
InChI InChI=1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38)
InChI Key BJCJYEYYYGBROF-UHFFFAOYSA-N
References
1. Luo H, Quan H, Xie C, Xu Y, Fu L, Lou L. (2010)
HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance.
Leukemia, 24 (10): 1807-9. [PMID:20703259]
2. Zhao J, Quan H, Xu Y, Kong X, Jin L, Lou L. (2014)
Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Cancer Sci, 105 (1): 117-25. [PMID:24205792]